Leerink Partners analyst David Risinger has maintained their bullish stance on ANAB stock, giving a Buy rating on February 12.
David Risinger has given his Buy rating due to a combination of factors that highlight the potential undervaluation and promising prospects of AnaptysBio’s offerings. The company’s recent presentation of its corporate deck provided a more detailed view of the initial Phase 2b data for rosnilimab, which demonstrated superior efficacy in bio-experienced rheumatoid arthritis patients when compared to competitors. This promising performance is a key factor in the positive outlook for the stock.
Additionally, AnaptysBio revealed new preclinical data for rosnilimab in the treatment of ulcerative colitis, which further supports its therapeutic potential. The data highlighted the expression of inflammatory pathway genes in UC colonic tissue, aligning with previous findings on the drug’s effectiveness. These insights, combined with management’s strategic plans and upcoming data releases, contribute to the assessment that ANAB shares are currently undervalued.
Risinger covers the Healthcare sector, focusing on stocks such as AnaptysBio, Eli Lilly & Co, and Regeneron. According to TipRanks, Risinger has an average return of 11.4% and a 56.95% success rate on recommended stocks.
In another report released on February 12, Wells Fargo also maintained a Buy rating on the stock with a $51.00 price target.